Search company, investor...

Founded Year

2001

Stage

Acquired | Acquired

Total Raised

$203.14M

About AcuFocus

AcuFocus focuses on ophthalmic medical devices within the healthcare industry. The company's main offerings include small-aperture intraocular products designed to address various unmet needs in eye care and help patients achieve optimal vision. These products work by filtering out peripheral defocused light, allowing only focused light to reach the retina, which provides a continuous depth of focus. It was founded in 2001 and is based in Irvine, California. In January 2023, AcuFocus was acquired by Bausch & Lomb UK.

Headquarters Location

32 Discovery Suite 200

Irvine, California, 92618,

United States

949-585-9511

Loading...

Loading...

AcuFocus Patents

AcuFocus has filed 50 patents.

The 3 most popular patent topics include:

  • ophthalmology
  • vision
  • eye surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/18/2021

10/3/2023

Ophthalmology, Vision, Geometrical optics, Eye surgery, Disorders of sclera and cornea

Grant

Application Date

2/18/2021

Grant Date

10/3/2023

Title

Related Topics

Ophthalmology, Vision, Geometrical optics, Eye surgery, Disorders of sclera and cornea

Status

Grant

Latest AcuFocus News

Global Intraocular Lens Market to Garner $6.5 Billion by 2031 With CAGR of 5.6%: Says Allied Market Research

Nov 13, 2023

Pune, INDIA Wilmington, Delaware, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Intraocular Lens Market by Type (Monofocal Intraocular Lens, Premium Intraocular Lens), by Material (Polymethylmethacrylate, Silicone, Hydrophobic and Hydrophilic Acrylic Materials), by End User (Hospitals, Ambulatory Surgery Centers, Ophthalmology Clinics, and Eye Research Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2031." The report states that the intraocular lens industry size is expected to value at $6.5 billion by 2031, having witnessed a revenue of $3.8 billion in 2021, with a notable CAGR of 5.6% from 2022 to 2031. Factors influencing the growth of the market: The global intraocular lens market is expanding rapidly due to the development of latest intraocular lens by the frontrunners, surge in prevalence of cataract surgery, and growth in adoption of innovative premium intraocular lens. The market's growth is impeded by postoperative complications and an unsupportive reimbursement environment for premium lenses, including refractive errors. Nevertheless, a surge in the number of product approvals and technological advancements are estimated to offer ample growth to the market in the upcoming years. Request Sample of the Report on Intraocular Lens Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/2092 The monofocal intraocular lens segment to continue its supremacy by 2031 On the basis of the type, the monofocal intraocular lens segment grabbed the highest share in 2021, accounting for more than three-fifths of the global intraocular lens market and is estimated to rule the roost throughout the forecast timeframe. Numerous ophthalmologists prefer this type of lens, and as a result, it has taken the lead in terms of revenue within this segment. However, the premium intraocular lens segment would showcase the fastest growth with 7.2% CAGR during the forecast period of 2022 to 2031, because they are effective in treatment of intricate retinal issues. The hospitals segment is expected to sustain its dominant position throughout the forecast period. On the basis of end user, the hospitals segment grabbed the highest market share f more than half of the global intraocular lens market in 2021 and is expected to retain its dominance throughout the forecast timeframe. The growth is driven by an increase in the number of cataract surgeries conducted in inpatient settings. The ophthalmology clinics segment, on the other hand, is anticipated to portray the highest CAGR of 6.8% throughout the forecast timeframe, owing to surge in number of discrete ophthalmic clinics. Want to Explore More, Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/2092 Recent Developments in the Intraocular Lens Market In October 2023, Bausch + Lomb, a leading global eye health company announced the launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) with Intermediate Optimized (IO) optics in the U.S. In January 2023, Bausch + Lomb Corporation, a leading global eye health company announced that Bausch + Lomb has acquired AcuFocus. This acquisition will help to expand its product portfolio. AcuFocus has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eye care, including the IC-8 Apthera intraocular lens (IOL). In January 2021, Alcon the global leader in eye care has commercially launched the first and only non-diffractive extended depth of focus intraocular lens (IOL) in the U.S. the AcrySof IQ VivityTM IOL (Vivity). In August 2020, Johnson & Johnson Vision, a global leader in eye health launched the TECNIS Synergy and TECNIS Eyhance Intraocular Lenses (IOLs) for the treatment of cataracts in Canada. North America to uphold the leading position by 2031 The regional analysis in the report indicates that the market across North America was largest in 2021, contributing to nearly two-fifths of the global intraocular lens market revenue and is estimated to continue its supremacy from 2022 to 2031. This can be attributed to the favorable reimbursement policies for cataract treatment within North America. The Asia-Pacific region, on the other hand, is estimated to display the fastest CAGR of 6.9% throughout the forecast timeframe. High geriatric population with possibilities of cataract and rise in awareness related to advanced cataract treatment choices contributed to the expansion of the intraocular lens market across the region. For Procurement Information - https://www.alliedmarketresearch.com/purchase-enquiry/2092

AcuFocus Frequently Asked Questions (FAQ)

  • When was AcuFocus founded?

    AcuFocus was founded in 2001.

  • Where is AcuFocus's headquarters?

    AcuFocus's headquarters is located at 32 Discovery, Irvine.

  • What is AcuFocus's latest funding round?

    AcuFocus's latest funding round is Acquired.

  • How much did AcuFocus raise?

    AcuFocus raised a total of $203.14M.

  • Who are the investors of AcuFocus?

    Investors of AcuFocus include Bausch & Lomb UK, Versant Ventures, KKR, SightLine Partners, SV Health Investors and 10 more.

  • Who are AcuFocus's competitors?

    Competitors of AcuFocus include Spineology, Neoss, Alcon, Paradigm Spine, SOLX and 7 more.

Loading...

Compare AcuFocus to Competitors

Neoss Logo
Neoss

Neoss develops dental implant technology. It helps in reducing patient treatment time, optimizing inventory control, and superior outcomes for patients. It was founded in 2000 and is based in Zurich, Switzerland.

Spineology Logo
Spineology

Spineology provides anatomy-conserving spinal technologies for surgeons and their patients. Its surgical techniques conserve spinal bone, ligament, and muscle tissue, committed to increasing procedural efficiency, reducing surgical morbidity, and accelerating patient recovery. The company was founded in 1996 and is based in Saint Paul, Minnesota.

E
EyeTechCare

EyeTechCare is a company focused on the healthcare sector, specifically in the field of glaucoma treatment. The company offers non-invasive solutions for glaucoma patients, utilizing focused ultrasound technology to manage the condition. EyeTechCare primarily serves the healthcare industry, particularly those dealing with eye health and glaucoma treatment. It was founded in 2008 and is based in Rillieux-la-Pape, France.

N
NovaLign Orthopaedics

NovaLign Orthopaedics, formerly known as OsteoLign, is developing a minimally invasive solution for long bone fractures.

S
Simpirica Spine

Simpirica is developing a dynamic stabilization system designed to stabilize the spine in flexion and help patients return to more healthy, active lifestyles. The company's lead product, the LimiFlex Spinal Stabilization System, is typically used in conjunction with a surgical decompression for the treatment of lumbar spinal stenosis with or without degenerative spondylolisthesis.

D
Dental Implants

Dental Implant Technologies (DIT) is a San Antonio based dental technology company providing an end to end suite of integrated implant based restorative services and products for dental patients requiring the replacement of most or all of their teeth. In the United States alone this market includes 30M individuals or a served addressable market of $96B including $26B for DIT's products and services. It is based in Scottsdale, Arizona.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.